ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Costs and use of antimigraine drugs in Italy: a ten-year analysis of national data.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigraine is a highly prevalent neurological disorder associated with substantial disability and economic burden. Considering the recent introduction of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), expenditure analysis are needed to evaluate a rapidly evolving therapeutic field. Therefore, we analyzed national pharmaco-utilization trends of antimigraine drugs in Italy over the decade 2014-2023 using publicly available data from the "Osservatorio Nazionale sull'Impiego dei Medicinali" (OsMed) report of the Italian Medicines Agency (AIFA).
methodsAll antimigraine drugs reimbursed by the National Health Service and classified under the antimigraine drug group were included. Indicators comprised defined daily doses (DDD) per 1,000 inhabitants per day, per-capita expenditure, cost per DDD, and user-level measures.
resultsIn 2023, 0.6% of the Italian population received antimigraine drugs, with a median age of 51 years and a marked female predominance. National expenditure reached €92 million, corresponding to €1.56 per capita and 0.4% of pharmaceutical spending, with consumption of 1.2 DDD/1,000 inhabitants per day. Triptans accounted for 65% of costs and 75% of use, remaining the dominant class. Anti-CGRP mAbs, introduced in 2019, rapidly expanded to represent 35% of expenditure in 2023, with the highest cost per DDD. Historical classes such as ergot alkaloids and other antimigraine agents declined to negligible levels. Over the decade, consumption increased modestly (compound annual growth rate + 3.1%) while expenditure rose more slowly (+ 1.5%), with costs escalation after the introduction of anti-CGRP mAbs. Of note, the overall expending for novel anti-CGRP drugs remains limited when considering the high prevalence of migraine.
conclusionsThese findings highlight the evolving therapeutic scenario of migraine in Italy, the impact of innovation on budget, and the need for real-world studies integrating pharmaco-utilization, direct and indirect costs and clinical outcomes.
Indexed as
Identifiers
42675367What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.